Delay Vote On Cannabis Reclassification – Chair Of UN Commission On Narcotic Drugs Recommends 14/03/2019 Elaine Ruth Fletcher The UN Commission on Narcotic Drugs appears set to delay any consideration this year of a recent World Health Organization recommendation to reschedule the status of cannabis and cannabis-related substances from “particularly dangerous” to a less dangerous category – with no timeline indicated for when the Commission might actually take up the contentious issue. Image […] Continue reading -> UNAIDS Urges Worldwide Reform Of Drug Policies – Links To HIV Prevention, Human Rights 14/03/2019 Elaine Ruth Fletcher UNAIDS urged UN member states convening today in Vienna for the UN Commission on Narcotic Drugs to enact sweeping reforms of policies towards injecting drug users, most of whom lack critical access to basic “harm reduction” services that could prevent them from becoming infected with HIV. Continue reading -> WHA Resolution For Transparent Drug Pricing: Italy Speaks Out 12/03/2019 Elaine Ruth Fletcher Italy’s Minister of Health spoke out publicly today at a press conference in Rome on the proposed World Health Assembly resolution on drug price transparency, while an open letter published on the Ministry’s website called on other World Health Organization member states to support the initiative. Continue reading -> United Nations Environment Assembly Touches Key Global Health Themes 11/03/2019 Elaine Ruth Fletcher The Fourth United Nations Environment Assembly (UNEA) opened today in Nairobi against the sober backdrop of yesterday’s tragic crash of Ethiopian Airlines flight 302 en route to the Kenyan capital, killing at least 22 UN staff and humanitarian aid workers, including passengers headed to the UNEA meeting. Image Credits: Baz Ratner/Reuters, @CCAC coalition. Continue reading -> CEPI Board Reaffirms Commitment To Safeguard Access To New Vaccines 08/03/2019 Elaine Ruth Fletcher The Coalition for Epidemic Preparedness Innovations (CEPI), an innovative collaboration of governments, UN agencies, foundations and the private sector, has reaffirmed its commitment to safeguard and promote equitable access to new vaccines under development to head off the risk of disease outbreaks, epidemics and pandemics that threaten global health. Image Credits: CEPI / CureVac. Continue reading -> Global Health Agencies Face Yawning Gaps In Gender Equality – New 50/50 Report 07/03/2019 Elaine Ruth Fletcher Stark gender pay and power gaps remain a fact of life in leading global health organisations, according to a new Global Health 50/50 report on gender-equality in nearly 200 workplaces, including United Nations and national development agencies as well as non-profit organisations, research institutions and private sector firms. Image Credits: Global Health 50/50. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> WHO: Global Health Expenditure Rising But Public Outlays Lag In Low Income Countries 20/02/2019 Elaine Ruth Fletcher Global health expenditure is rising worldwide, and the pace is most rapid in low- and middle-income countries where growth in all forms of spending (public, private and donor aid) is now averaging 6% annually as compared to 4% in high-income countries, according to a World Health Organization report released today. Continue reading -> Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> ‘Netflix’ Pricing Model Eases Australians’ Access To Expensive Hepatitis C Drugs 14/02/2019 Elaine Ruth Fletcher An innovative five-year agreement between the Australian government and pharmaceutical companies, involving a lump sum payment of about US$ 766 million for an unlimited five-year supply of the most advanced Hepatitis C (HCV) drugs, has reduced the per-patient costs of these cutting-edge treatments by roughly 85%, according to a study today in the New England Journal of Medicine. Continue reading -> Posts navigation Older postsNewer posts
UNAIDS Urges Worldwide Reform Of Drug Policies – Links To HIV Prevention, Human Rights 14/03/2019 Elaine Ruth Fletcher UNAIDS urged UN member states convening today in Vienna for the UN Commission on Narcotic Drugs to enact sweeping reforms of policies towards injecting drug users, most of whom lack critical access to basic “harm reduction” services that could prevent them from becoming infected with HIV. Continue reading -> WHA Resolution For Transparent Drug Pricing: Italy Speaks Out 12/03/2019 Elaine Ruth Fletcher Italy’s Minister of Health spoke out publicly today at a press conference in Rome on the proposed World Health Assembly resolution on drug price transparency, while an open letter published on the Ministry’s website called on other World Health Organization member states to support the initiative. Continue reading -> United Nations Environment Assembly Touches Key Global Health Themes 11/03/2019 Elaine Ruth Fletcher The Fourth United Nations Environment Assembly (UNEA) opened today in Nairobi against the sober backdrop of yesterday’s tragic crash of Ethiopian Airlines flight 302 en route to the Kenyan capital, killing at least 22 UN staff and humanitarian aid workers, including passengers headed to the UNEA meeting. Image Credits: Baz Ratner/Reuters, @CCAC coalition. Continue reading -> CEPI Board Reaffirms Commitment To Safeguard Access To New Vaccines 08/03/2019 Elaine Ruth Fletcher The Coalition for Epidemic Preparedness Innovations (CEPI), an innovative collaboration of governments, UN agencies, foundations and the private sector, has reaffirmed its commitment to safeguard and promote equitable access to new vaccines under development to head off the risk of disease outbreaks, epidemics and pandemics that threaten global health. Image Credits: CEPI / CureVac. Continue reading -> Global Health Agencies Face Yawning Gaps In Gender Equality – New 50/50 Report 07/03/2019 Elaine Ruth Fletcher Stark gender pay and power gaps remain a fact of life in leading global health organisations, according to a new Global Health 50/50 report on gender-equality in nearly 200 workplaces, including United Nations and national development agencies as well as non-profit organisations, research institutions and private sector firms. Image Credits: Global Health 50/50. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> WHO: Global Health Expenditure Rising But Public Outlays Lag In Low Income Countries 20/02/2019 Elaine Ruth Fletcher Global health expenditure is rising worldwide, and the pace is most rapid in low- and middle-income countries where growth in all forms of spending (public, private and donor aid) is now averaging 6% annually as compared to 4% in high-income countries, according to a World Health Organization report released today. Continue reading -> Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> ‘Netflix’ Pricing Model Eases Australians’ Access To Expensive Hepatitis C Drugs 14/02/2019 Elaine Ruth Fletcher An innovative five-year agreement between the Australian government and pharmaceutical companies, involving a lump sum payment of about US$ 766 million for an unlimited five-year supply of the most advanced Hepatitis C (HCV) drugs, has reduced the per-patient costs of these cutting-edge treatments by roughly 85%, according to a study today in the New England Journal of Medicine. Continue reading -> Posts navigation Older postsNewer posts
WHA Resolution For Transparent Drug Pricing: Italy Speaks Out 12/03/2019 Elaine Ruth Fletcher Italy’s Minister of Health spoke out publicly today at a press conference in Rome on the proposed World Health Assembly resolution on drug price transparency, while an open letter published on the Ministry’s website called on other World Health Organization member states to support the initiative. Continue reading -> United Nations Environment Assembly Touches Key Global Health Themes 11/03/2019 Elaine Ruth Fletcher The Fourth United Nations Environment Assembly (UNEA) opened today in Nairobi against the sober backdrop of yesterday’s tragic crash of Ethiopian Airlines flight 302 en route to the Kenyan capital, killing at least 22 UN staff and humanitarian aid workers, including passengers headed to the UNEA meeting. Image Credits: Baz Ratner/Reuters, @CCAC coalition. Continue reading -> CEPI Board Reaffirms Commitment To Safeguard Access To New Vaccines 08/03/2019 Elaine Ruth Fletcher The Coalition for Epidemic Preparedness Innovations (CEPI), an innovative collaboration of governments, UN agencies, foundations and the private sector, has reaffirmed its commitment to safeguard and promote equitable access to new vaccines under development to head off the risk of disease outbreaks, epidemics and pandemics that threaten global health. Image Credits: CEPI / CureVac. Continue reading -> Global Health Agencies Face Yawning Gaps In Gender Equality – New 50/50 Report 07/03/2019 Elaine Ruth Fletcher Stark gender pay and power gaps remain a fact of life in leading global health organisations, according to a new Global Health 50/50 report on gender-equality in nearly 200 workplaces, including United Nations and national development agencies as well as non-profit organisations, research institutions and private sector firms. Image Credits: Global Health 50/50. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> WHO: Global Health Expenditure Rising But Public Outlays Lag In Low Income Countries 20/02/2019 Elaine Ruth Fletcher Global health expenditure is rising worldwide, and the pace is most rapid in low- and middle-income countries where growth in all forms of spending (public, private and donor aid) is now averaging 6% annually as compared to 4% in high-income countries, according to a World Health Organization report released today. Continue reading -> Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> ‘Netflix’ Pricing Model Eases Australians’ Access To Expensive Hepatitis C Drugs 14/02/2019 Elaine Ruth Fletcher An innovative five-year agreement between the Australian government and pharmaceutical companies, involving a lump sum payment of about US$ 766 million for an unlimited five-year supply of the most advanced Hepatitis C (HCV) drugs, has reduced the per-patient costs of these cutting-edge treatments by roughly 85%, according to a study today in the New England Journal of Medicine. Continue reading -> Posts navigation Older postsNewer posts
United Nations Environment Assembly Touches Key Global Health Themes 11/03/2019 Elaine Ruth Fletcher The Fourth United Nations Environment Assembly (UNEA) opened today in Nairobi against the sober backdrop of yesterday’s tragic crash of Ethiopian Airlines flight 302 en route to the Kenyan capital, killing at least 22 UN staff and humanitarian aid workers, including passengers headed to the UNEA meeting. Image Credits: Baz Ratner/Reuters, @CCAC coalition. Continue reading -> CEPI Board Reaffirms Commitment To Safeguard Access To New Vaccines 08/03/2019 Elaine Ruth Fletcher The Coalition for Epidemic Preparedness Innovations (CEPI), an innovative collaboration of governments, UN agencies, foundations and the private sector, has reaffirmed its commitment to safeguard and promote equitable access to new vaccines under development to head off the risk of disease outbreaks, epidemics and pandemics that threaten global health. Image Credits: CEPI / CureVac. Continue reading -> Global Health Agencies Face Yawning Gaps In Gender Equality – New 50/50 Report 07/03/2019 Elaine Ruth Fletcher Stark gender pay and power gaps remain a fact of life in leading global health organisations, according to a new Global Health 50/50 report on gender-equality in nearly 200 workplaces, including United Nations and national development agencies as well as non-profit organisations, research institutions and private sector firms. Image Credits: Global Health 50/50. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> WHO: Global Health Expenditure Rising But Public Outlays Lag In Low Income Countries 20/02/2019 Elaine Ruth Fletcher Global health expenditure is rising worldwide, and the pace is most rapid in low- and middle-income countries where growth in all forms of spending (public, private and donor aid) is now averaging 6% annually as compared to 4% in high-income countries, according to a World Health Organization report released today. Continue reading -> Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> ‘Netflix’ Pricing Model Eases Australians’ Access To Expensive Hepatitis C Drugs 14/02/2019 Elaine Ruth Fletcher An innovative five-year agreement between the Australian government and pharmaceutical companies, involving a lump sum payment of about US$ 766 million for an unlimited five-year supply of the most advanced Hepatitis C (HCV) drugs, has reduced the per-patient costs of these cutting-edge treatments by roughly 85%, according to a study today in the New England Journal of Medicine. Continue reading -> Posts navigation Older postsNewer posts
CEPI Board Reaffirms Commitment To Safeguard Access To New Vaccines 08/03/2019 Elaine Ruth Fletcher The Coalition for Epidemic Preparedness Innovations (CEPI), an innovative collaboration of governments, UN agencies, foundations and the private sector, has reaffirmed its commitment to safeguard and promote equitable access to new vaccines under development to head off the risk of disease outbreaks, epidemics and pandemics that threaten global health. Image Credits: CEPI / CureVac. Continue reading -> Global Health Agencies Face Yawning Gaps In Gender Equality – New 50/50 Report 07/03/2019 Elaine Ruth Fletcher Stark gender pay and power gaps remain a fact of life in leading global health organisations, according to a new Global Health 50/50 report on gender-equality in nearly 200 workplaces, including United Nations and national development agencies as well as non-profit organisations, research institutions and private sector firms. Image Credits: Global Health 50/50. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> WHO: Global Health Expenditure Rising But Public Outlays Lag In Low Income Countries 20/02/2019 Elaine Ruth Fletcher Global health expenditure is rising worldwide, and the pace is most rapid in low- and middle-income countries where growth in all forms of spending (public, private and donor aid) is now averaging 6% annually as compared to 4% in high-income countries, according to a World Health Organization report released today. Continue reading -> Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> ‘Netflix’ Pricing Model Eases Australians’ Access To Expensive Hepatitis C Drugs 14/02/2019 Elaine Ruth Fletcher An innovative five-year agreement between the Australian government and pharmaceutical companies, involving a lump sum payment of about US$ 766 million for an unlimited five-year supply of the most advanced Hepatitis C (HCV) drugs, has reduced the per-patient costs of these cutting-edge treatments by roughly 85%, according to a study today in the New England Journal of Medicine. Continue reading -> Posts navigation Older postsNewer posts
Global Health Agencies Face Yawning Gaps In Gender Equality – New 50/50 Report 07/03/2019 Elaine Ruth Fletcher Stark gender pay and power gaps remain a fact of life in leading global health organisations, according to a new Global Health 50/50 report on gender-equality in nearly 200 workplaces, including United Nations and national development agencies as well as non-profit organisations, research institutions and private sector firms. Image Credits: Global Health 50/50. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> WHO: Global Health Expenditure Rising But Public Outlays Lag In Low Income Countries 20/02/2019 Elaine Ruth Fletcher Global health expenditure is rising worldwide, and the pace is most rapid in low- and middle-income countries where growth in all forms of spending (public, private and donor aid) is now averaging 6% annually as compared to 4% in high-income countries, according to a World Health Organization report released today. Continue reading -> Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> ‘Netflix’ Pricing Model Eases Australians’ Access To Expensive Hepatitis C Drugs 14/02/2019 Elaine Ruth Fletcher An innovative five-year agreement between the Australian government and pharmaceutical companies, involving a lump sum payment of about US$ 766 million for an unlimited five-year supply of the most advanced Hepatitis C (HCV) drugs, has reduced the per-patient costs of these cutting-edge treatments by roughly 85%, according to a study today in the New England Journal of Medicine. Continue reading -> Posts navigation Older postsNewer posts
Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> WHO: Global Health Expenditure Rising But Public Outlays Lag In Low Income Countries 20/02/2019 Elaine Ruth Fletcher Global health expenditure is rising worldwide, and the pace is most rapid in low- and middle-income countries where growth in all forms of spending (public, private and donor aid) is now averaging 6% annually as compared to 4% in high-income countries, according to a World Health Organization report released today. Continue reading -> Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> ‘Netflix’ Pricing Model Eases Australians’ Access To Expensive Hepatitis C Drugs 14/02/2019 Elaine Ruth Fletcher An innovative five-year agreement between the Australian government and pharmaceutical companies, involving a lump sum payment of about US$ 766 million for an unlimited five-year supply of the most advanced Hepatitis C (HCV) drugs, has reduced the per-patient costs of these cutting-edge treatments by roughly 85%, according to a study today in the New England Journal of Medicine. Continue reading -> Posts navigation Older postsNewer posts
WHO: Global Health Expenditure Rising But Public Outlays Lag In Low Income Countries 20/02/2019 Elaine Ruth Fletcher Global health expenditure is rising worldwide, and the pace is most rapid in low- and middle-income countries where growth in all forms of spending (public, private and donor aid) is now averaging 6% annually as compared to 4% in high-income countries, according to a World Health Organization report released today. Continue reading -> Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> ‘Netflix’ Pricing Model Eases Australians’ Access To Expensive Hepatitis C Drugs 14/02/2019 Elaine Ruth Fletcher An innovative five-year agreement between the Australian government and pharmaceutical companies, involving a lump sum payment of about US$ 766 million for an unlimited five-year supply of the most advanced Hepatitis C (HCV) drugs, has reduced the per-patient costs of these cutting-edge treatments by roughly 85%, according to a study today in the New England Journal of Medicine. Continue reading -> Posts navigation Older postsNewer posts
Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> ‘Netflix’ Pricing Model Eases Australians’ Access To Expensive Hepatitis C Drugs 14/02/2019 Elaine Ruth Fletcher An innovative five-year agreement between the Australian government and pharmaceutical companies, involving a lump sum payment of about US$ 766 million for an unlimited five-year supply of the most advanced Hepatitis C (HCV) drugs, has reduced the per-patient costs of these cutting-edge treatments by roughly 85%, according to a study today in the New England Journal of Medicine. Continue reading -> Posts navigation Older postsNewer posts
‘Netflix’ Pricing Model Eases Australians’ Access To Expensive Hepatitis C Drugs 14/02/2019 Elaine Ruth Fletcher An innovative five-year agreement between the Australian government and pharmaceutical companies, involving a lump sum payment of about US$ 766 million for an unlimited five-year supply of the most advanced Hepatitis C (HCV) drugs, has reduced the per-patient costs of these cutting-edge treatments by roughly 85%, according to a study today in the New England Journal of Medicine. Continue reading -> Posts navigation Older postsNewer posts